Photo by robertbye from unsplash
Artesunate, approved by the Food and Drug Administration in 2020 as a new treatment for severe malaria, also shows anti‐tumour activity against acute myeloid leukaemia (AML). However, the underlying molecular… Click to show full abstract
Artesunate, approved by the Food and Drug Administration in 2020 as a new treatment for severe malaria, also shows anti‐tumour activity against acute myeloid leukaemia (AML). However, the underlying molecular mechanism(s) of artesunate‐induced apoptosis and differentiation of AML is not clearly elucidated.
Keywords:
antimalarial clinical;
aml;
artesunate new;
activity;
new antimalarial;
drug
Journal Title: British Journal of Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!